Brokerage firm Deutsche Bank Downgrades its rating on Quintiles Transnational Holdings Inc(Q). The shares have been rated Hold. Previously, the analysts had a Buy rating on the shares. The rating by Deutsche Bank was issued on Feb 3, 2017.
In a different note, On Dec 16, 2016, Goldman Sachs said it Downgrades its rating on Quintiles Transnational Holdings Inc. The shares have been rated ‘Neutral’ by the firm. Mizuho said it Initiates Coverage On Quintiles Transnational Holdings Inc, according to a research note issued on Dec 13, 2016. In the research note, the firm Announces the price-target to $90 per share. The shares have been rated ‘Neutral’ by the firm.
Quintiles Transnational Holdings Inc (Q) made into the market gainers list on Tuesdays trading session with the shares advancing 0.31% or 0.24 points. Due to strong positive momentum, the stock ended at $77.99, which is also near the day’s high of $78.38. The stock began the session at $78.16 and the volume stood at 10,19,382 shares. The 52-week high of the shares is $81.45 and the 52 week low is $55.011. The company has a current market capitalization of $19,200 M and it has 24,61,81,560 shares in outstanding.
Quintiles Transnational Holdings Inc(Q) last announced its earnings results on Jul 27, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $1.17B. Analysts had an estimated revenue of $1.15B. Earnings per share were $0.93. Analysts had estimated an EPS of $0.91.
Several Insider Transactions has been reported to the SEC. On Nov 22, 2016, Jack M Greenberg (director) sold 2,000 shares at $79.77 per share price.Also, On Jun 10, 2016, Kevin K Gordon (EVP and COO) sold 24,000 shares at $66.41 per share price.On May 16, 2016, Annie H. Lo (director) purchased 502 shares at $64.80 per share price, according to the Form-4 filing with the securities and exchange commission.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services including commercial services such as contract pharmaceutical sales forces and healthcare business services such as phase research market access and consulting and health information analytics and technology consulting.